Pre-treatment bone turnover does not influence the level of the response to alendronate in postmenopausal osteoporosis at the bone tissue level
Authors' conclusion
The percentage response to ALN appeared independent of the baseline level of bone turnover. After treatment, the bone turnover tended to be similar in all BFR quartiles.
Study context
- Population
- Postmenopausal women with osteoporosis treated with alendronate 70 mg/week
- Participants
- 90 postmenopausal women
- Comparison
- Response to alendronate across quartiles of baseline bone formation rate
- 6 months alendronate (ALN)n = 44
- 12 months ALNn = 46
- Primary endpoint
- Changes in histomorphometric parameters of bone turnover (MS/BS, BFR/BS, Ac.f) after ALN according to baseline turnover (BFR/BS quartiles)
- Follow-up
- 6 or 12 months
Methodological detailspaired transiliac bone biopsies before and after treatment, quartiles of baseline BFR/BS
- Paired transiliac bone biopsies before and after treatment
- Quartiles of baseline BFR/BS
Primary result
As reported in the abstract
Response to ALN by baseline BFR/BS quartile
- After ALN, Ac.f remained significantly lower in first quartile vs third and fourth
- p < 0.03
Further findings
Baseline differences among BFR quartiles
- MS/BS and Ac.f significantly different among BFR quartiles
- P < 0.0001
- sCTX and sP1NP not significantly different among quartiles
Original publication
Pre-treatment bone turnover does not influence the level of the response to alendronate in postmenopausal osteoporosis at the bone tissue level. Osteoporos Int. Published 22 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →